Pre-registration for Visiopharm USCAP 2022 Seminar
Visiopharm has announced preregistration for their USCAP 2022 seminar.
AI-driven stain quality standardization of IHC
Featuring Marilyn M. Bui, MD, Ph.D., Moffitt Cancer Center and Martin Kristensson, Visiopharm
Wednesday, March 23rd, 2022
12:00 – 1:00 PM PST
Exhibitor seminar room 3 (West exhibit hall A).
If you can’t join in person, you should still sign up, as we’ll send you a link to watch the presentation at your leisure afterward.
About the seminar
The adoption of tissue-based companion diagnostic assays (CDx) has been growing steadily for cancer therapeutics. At the same time, the CDx interpretation protocols are becoming more complex yet the level of standardization of IHC stain quality remains a significant unmet need for diagnostic labs.
Data collected from 10 years of external proficiency testing shows that over 30% of labs fail these assessments for routine biomarkers and around 20% of labs fail for the breast panel. External proficiency testing (EPT) is an effective tool for quality improvement, however the frequency of EPT is relatively low – typically quarterly in US and even less frequently elsewhere in the world.
To address these challenges, Visiopharm has developed a novel AI-based approach that allows diagnostic labs to continuously, accurately and reproducibly measure and monitor stain quality – a step closer to IHC standardization.
What you will learn
- Understand the challenges related to IHC staining standardization for existing and novel CDx biomarkers
- Discuss the benefits and limitations of external proficiency testing schemes
- Describe how AI / deep learning in combination with cell line controls be utilized to monitor stain quality continuously and aid with documentation of quality
- Understand practical implications of the approach
